Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (3)

Search Parameters:
Authors = Lucio Mango ORCID = 0000-0002-8078-3038

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
6 pages, 1074 KiB  
Communication
Lymphoscintigraphic Indications in the Diagnosis, Management and Prevention of Secondary Lymphedema
by Lucio Mango
Radiation 2023, 3(1), 40-45; https://doi.org/10.3390/radiation3010004 - 15 Feb 2023
Cited by 2 | Viewed by 6192
Abstract
Secondary lymphedema is caused by damage to the lymphatic system, often following an oncological tumor removal intervention, or even by an accident. The diagnosis of lymphedema is not easy, because the disease can also be confused with other clinical manifestations (for example, venous [...] Read more.
Secondary lymphedema is caused by damage to the lymphatic system, often following an oncological tumor removal intervention, or even by an accident. The diagnosis of lymphedema is not easy, because the disease can also be confused with other clinical manifestations (for example, venous insufficiency edema), though an experienced Lymphologist is usually able to diagnose it with good accuracy. To confirm the diagnosis, it is often necessary to resort to specialist imaging tests for an anatomo-functional definition of the pathology. Among these, lymphoscintigraphy is confirmed as the “gold standard” procedure for the diagnosis of lymphedema. Lymphoscintigraphy has been included in the Italian Guidelines by the Ministry of Health. Full article
(This article belongs to the Section Radiation in Medical Imaging)
Show Figures

Figure 1

8 pages, 17353 KiB  
Case Report
Differentiated Thyroid Carcinoma and Late Onset of Lung Distant Metastasis. A Case Report
by Alessandro Semprebene, Anna Maria Mangano, Guido Ventroni, Raffaella Barone, Francesca Romana Piro and Lucio Mango
Reports 2019, 2(1), 6; https://doi.org/10.3390/reports2010006 - 2 Feb 2019
Viewed by 3297
Abstract
Background: Differentiated thyroid carcinoma (DTC), which includes the papillary and follicular variants, is a common neoplasm. DTC has a very high cure rate and is treated surgically, usually followed by ablation of the post-surgical remnant with radioiodine. Case Presentation: The case of a [...] Read more.
Background: Differentiated thyroid carcinoma (DTC), which includes the papillary and follicular variants, is a common neoplasm. DTC has a very high cure rate and is treated surgically, usually followed by ablation of the post-surgical remnant with radioiodine. Case Presentation: The case of a 68-year-old male patient who underwent a minimally invasive complete thyroidectomy on July 4, 2007 for capsulated follicular carcinoma with margins of excision exempted from neoplastic infiltration (AJCC 2002 pT2 PNX PMX) is presented. Discussion: As the patient showed the presence of a pulmonary metastasis after 11 years, the potential implications of DTC follow-up management are here summarized. Conclusions: Follow up must be continued throughout life. Full article
Show Figures

Figure 1

7 pages, 2169 KiB  
Case Report
Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
by Anna Maria Mangano, Massimiliano Pacilio, Pasquale Ialongo, Alessandro Semprebene, Guido Ventroni and Lucio Mango
Diagnostics 2018, 8(1), 18; https://doi.org/10.3390/diagnostics8010018 - 27 Feb 2018
Cited by 4 | Viewed by 6570
Abstract
Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with 223Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on repeated bone scans [...] Read more.
Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with 223Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on repeated bone scans after therapy. We also discuss the possibility of continuing the 223Ra-dichloride therapy over the six planned administrations by administering other cycles at the same dose or at higher doses, if shown to be devoid of a significant increase in side effects, based on dosimetry considerations. Full article
(This article belongs to the Special Issue Imaging of Bone Metastases in Oncology)
Show Figures

Figure 1

Back to TopTop